Clinical Trials on brca2 Mutation Carrier in Hungary

Total 16 results

AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
AstraZeneca

Completed

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

HER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 Mutations

Italy, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
University of Debrecen

Enrolling by invitation

Effect of Sour Cherry Anthocyanins on Healthy Human Saliva

Dental Caries

Hungary
Semmelweis University

Completed

Short- and Long Term Antibacterial Effects of a Single Rinse With Different Mouthwashes: a Randomized Clinical Trial

Gingival Diseases | Caries

Hungary
Guerbet

Completed

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Blood Brain Barrier Defect | CNS Lesion

Korea, Republic of, United States, Czechia, Italy, Belgium, Poland, Hungary, Mexico
Guerbet

Completed

Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PICTURE)

Blood Brain Barrier Defect | CNS Lesion

United States, Spain, Korea, Republic of, Taiwan, France, Hungary, Belgium, Germany, Italy, Mexico, Poland
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Italy, Spain, Belgium, Poland, Canada, Korea, Republic of, Brazil, Czechia, Hungary, Israel, Argentina, Mexico
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Stealth BioTherapeutics Inc.

Active, not recruiting

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) (NuPower)

Mitochondrial Diseases | Mitochondrial Myopathies | Mitochondrial Complex I Deficiency | Mitochondrial Pathology | Mitochondrial DNA Depletion | Mitochondrial DNA Mutation | Mitochondrial DNA Deletion | Mitochondrial Metabolism Defect

Spain, United States, Italy, Netherlands, Australia, Germany, Hungary, New Zealand, Norway, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
AstraZeneca

Completed

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)

BRCA or HRR+ Mutated Ovarian Cancer Patients

Italy, Spain, Canada, Czechia, Poland, United Kingdom, Hungary, Bulgaria
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation

Clinical Trials on brca2 Mutation Carrier in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations